Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Melissa Lynne Johnson, Manish R. Patel, Lillian L. Siu, Mark Kozloff, Raid Aljumaily, Ulka N. Vaishampayan | ||||||||||||
Title | Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.212 | ||||||||||||
Abstract Text | J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ezabenlimab | Ezabenlimab | 0 | 3 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ezabenlimab | BI754091|BI-754091|BI 754091 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|